Aradigm to Host Corporate Update Conference Call on June 26
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (Nasdaq:ARDM) (the "Company") will host a corporate update conference call at 8:00 am ET (5:00 am PT) on Thursday, June 26, 2014.
The Company will review recent significant milestones, as well as progress with the Pulmaquin® program in non-cystic fibrosis bronchiectasis.
Conference Call Information:
Date: Thursday, June 26, 2014
Time: 8:00 am ET/ 5:00 am PT
US Dial-in (Toll Free): 1-844-864-9348
Conference ID: 65852423
A replay of the call will be available through August 26, 2014. To access the replay, please call 1-404-537-3406 or 1-855-859-2056. The replay passcode is 65852423.
Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. Aradigm has product candidates addressing the treatment of non-cystic fibrosis bronchiectasis (non-CF BE), cystic fibrosis and prevention of respiratory and other diseases in tobacco smokers through smoking cessation. Aradigm is also developing Pulmaquin and a liposomal ciprofloxacin formulation as potential medications for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, Q fever and inhaled anthrax.
Aradigm has been granted orphan drug designations for liposomal ciprofloxacin for cystic fibrosis (CF) in the U.S. and the E.U., and liposomal ciprofloxacin and free ciprofloxacin for inhalation for the management of bronchiectasis in the U.S. In addition, the U.S. Food and Drug Administration (FDA) has designated Pulmaquin as a Qualified Infectious Disease Product (QIDP). The QIDP designation is granted for treatment of non-CF BE patients with chronic lung infections with Pseudomonas aeruginosa.
More information about Aradigm can be found at www.aradigm.com.
Aradigm, Pulmaquin and the Aradigm Logo are registered trademarks of Aradigm Corporation.